Navigation Links
ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the Association for Research in Vision and Ophthalmology (ARVO) 2009 Annual Meeting
Date:5/7/2009

for efficacy as a twice-a-day and once-a-day drop respectively.

In a separate poster presentation titled "Bepotastine Besilate Ophthalmic Solution 1.5% Reduces Tearing at 8 Hours Following Dosing in a Multi-Site Clinical Trial Using the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis", ISTA demonstrated positive results from a multi-center, double-masked, placebo-controlled, clinical study with 86 patients who were randomized to receive either Bepreve 1.5% or placebo in both eyes in three CAC tests spaced two weeks apart. The results showed Bepreve 1.5% was statistically superior to placebo for at least 8 hours after ophthalmic dosing for reducing CAC-induced tearing.

In another poster presentation titled "The Safety of the Anti-Histamine Bepotastine Besilate Ophthalmic Solution in a Healthy Pediatric Population from Ten to Seventeen Years of Age", ISTA demonstrated Bepreve 1.5% dosed in both eyes twice daily for six weeks was safe in a healthy pediatric population from 10-17 years of age. The pediatric subjects in this age group (n = 45) were among 861 patients enrolled in this masked, randomized, placebo-controlled clinical trial, with a randomization of 2:1 (Bepreve 1.5%:placebo). The proportion of subjects in the Bepreve 1.5% treatment group with an adverse event (22.5%) was very similar to that seen for subjects instilling placebo (20.0%). No serious adverse events were reported during the clinical trial for any pediatric subject.

Earlier in the week, the Company presented additional results from clinical studies with Bepreve 1.0%, as well as data from a clinical study with the Company's Xibrom(TM) (bromfenac ophthalmic solution 0.09%) product and laboratory results with Vitrase(R) (hyaluronidase injection). The results were presented in the following poster presentations:

Bepotastine Besilate Ophthalmic Solution 1.0% Rapidly Reduces Conjunctival
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014 Research and Markets ( ... "Micro Market Monitor: North American Dermatology Diagnostic ... http://photos.prnewswire.com/prnh/20130307/600769 ... which has resulted in fueling the overall demand ... purpose of these dermatology devices is to assist ...
(Date:12/19/2014)... Baptist Health Lexington is the first facility in ... Atrial Fibrillation with Electrophysiology Services (EPS) Accreditation status from the ... is the most common cardiac arrhythmia and has become recognized ... to stroke and possible death. More than 5 million patients ... fibrillation and the numbers are rapidly increasing as the population ...
(Date:12/17/2014)... AMSTERDAM and SAN DIEGO , ... PHG ; AEX: PHIA) and Volcano Corporation (NASDAQ: ... and measurement solutions for cardiovascular applications, today announced that they ... agreement, Philips will commence a tender offer to acquire all ... 18.00 per share, or a total equity purchase price of ...
Breaking Medicine Technology:Micro Market Monitor: North American Dermatology Diagnostic Devices Market 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 3Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8
... MOUNTAIN VIEW, Calif., April 4, 2011 VIVUS, Inc. (Nasdaq: ... patients treated with the investigational drug QNEXA® for two years ... medications as well as improvements in lipid levels following significant ... placebo group over two years. The data ...
... community pharmacy chain, has revealed that one in four* (24%) of ... has taken or applied medicines which they later discovered were out ... (53%) of people do not always check the expiry date of ... This is worrying considering that nearly one in ...
Cached Medicine Technology:Weight Loss With QNEXA® Over Two Years Provides Patients With Substantial Cardiovascular Benefits 2Weight Loss With QNEXA® Over Two Years Provides Patients With Substantial Cardiovascular Benefits 3Lloydspharmacy Reveals Over 11 Million Britons Risking Health by Taking Old Medicines 2Lloydspharmacy Reveals Over 11 Million Britons Risking Health by Taking Old Medicines 3
(Date:12/19/2014)... Sweetdressy.com , a leading wedding dress manufacturer ... of cheap prom dresses for ladies worldwide. The prom ... and clients can buy these dresses at the website ... cool cuts and delicate craftsmanship, and most of them ... Discount shipping costs are available for all of their ...
(Date:12/19/2014)... Branson, Missouri (PRWEB) December 19, 2014 ... a new official world record -- for the first time ... most prestigious record book, Guinness World Records 2015, listing the ... Steepest Wooden Roller Coaster. In additional awards announced this week, ... to See Christmas Lights in the US,” USA Today’s 10Best ...
(Date:12/19/2014)... dress is perfect for any occasion and is a vital ... has unveiled its new selection of evening dresses. Faddish clients ... Customers can view more at its website. , ... and praised by customers for many years. It focuses on ... order to expand its market share, the company has opened ...
(Date:12/19/2014)... 19, 2014 (HealthDay News) -- The intestinal bacteria that ... ulcerative colitis, may be inherited, researchers report. The ... , could help in efforts to prevent the disease ... colitis, the study authors added. "The intestinal bacteria, ... age can have a big impact on your health ...
(Date:12/19/2014)... News) -- Dense bunches of bacteria called biofilms can be ... finds. The researchers said these biofilms were especially ... presence of these biofilms may represent an increased likelihood of ... a person,s risk for the disease, the researchers said. ... may coat the mucus layer of cells lining the colon, ...
Breaking Medicine News(10 mins):Health News:Cheap Prom Dresses Online Now at Sweetdressy.com 2Health News:Silver Dollar City Nets New Titles: Guinness Book of World Records, Plus CNN Travel, USA Today & Fodor’s Top Places for Christmas Lights 2Health News:Attractive Evening Dresses Announced by Discount-Dress.com 2Health News:Crohn's, Colitis May Have Genetic Underpinnings, Study Finds 2Health News:Could Bacteria Play a Role in Colon Cancer? 2
... Inc.,publicly announces its offering of patient safety culture and ... clients since 2007,Pascal Metrics rapidly has become a worldwide ... other regulatory requirements, to reduce,costs, and - by making ... failure and errors. , ...
... Technologies(R), Inc.,("Global Med" or the "Company") (OTC ... technology company, today announced that its,European subsidiary, ... marketed as "Hemo Serveur" in France, to ... hospitals, representing 23,000 patient beds. For,Global Med, ...
... Parents and Professionals Shares Experience , Dealing ... , WASHINGTON, Dec. 2 ... equity, diversity, and quality of life for people with ... -- a free peer-to-peer resource directory accessible to ...
... show it could aid shift workers, people affected by jet ... drug tasimelteon helps treat temporary insomnia caused by jet lag ... clinical trials. , The phase II study included 39 people ... mg or 100 mg of tasimelteon, or a placebo. They ...
... ORLANDO, Fla., Dec. 2 MEDai, Inc., headquartered ... added a new module,to its existing suite of ... a population,s compliance to evidence-based medicine,guidelines and alerts ... protocol. The module Risk Navigator Guidelines(TM) provides,real-time ...
... Skipped Medical Care Due to Cost Issues- , ... survey released today by the National Women,s Health Resource Center (NWHRC) ... have failed to seek health care for themselves or their families ... their health has gotten worse over the past five years and ...
Cached Medicine News:Health News:Pascal Metrics Announces Patient Safety Culture Services Offering 2Health News:Global Med Technologies(R)' European Subsidiary to Provide Strategic Blood Transfusion Software for 21 Paris Hospitals 2Health News:Global Med Technologies(R)' European Subsidiary to Provide Strategic Blood Transfusion Software for 21 Paris Hospitals 3Health News:Global Med Technologies(R)' European Subsidiary to Provide Strategic Blood Transfusion Software for 21 Paris Hospitals 4Health News:New Website Links People With Disabilities to Peers for Help 2Health News:Drug Effective for Temporary Sleep Disruptions 2Health News:MEDai Evidence-Based Guideline Reporting Provides Decision Support at Point of Care 2Health News:Rising Health Costs Prompt Women to Neglect Health 2Health News:Rising Health Costs Prompt Women to Neglect Health 3Health News:Rising Health Costs Prompt Women to Neglect Health 4
... Mesh is constructed of Bard polypropylene mesh, ... over 40 years. Developed with the world ... Preshaped Mesh takes the guesswork out of ... sugeon performs a Lichtenstein inguinal hernia repair ...
... Kugel patch repair is a minimally invasive, ... a small 4-6 cm incision and requires ... performed through an open, anterior approach that ... anesthesia.,The Modified Kugel patch is a self-expanding ...
... PerFix plug technique, recommended for the ... indirect and direct inguinal hernias, provides ... technique, requiring less overall dissection and ... repair technique. The result is increased ...
... is constructed of knitted filaments of ... that used in PROLENE* Polypropylene Suture, ... The mesh is approximately,0.020 inches thick. ... suture, has been reported to be ...
Medicine Products: